Genmab A/S (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Analysts

Genmab A/S (NASDAQ:GMAB) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $45.20.

Several research analysts have weighed in on the stock. BMO Capital Markets restated an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Truist Financial dropped their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. Morgan Stanley reissued an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Finally, Redburn Atlantic began coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently made changes to their positions in GMAB. Allspring Global Investments Holdings LLC boosted its position in Genmab A/S by 123.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock valued at $81,000 after purchasing an additional 1,787 shares during the period. Blue Trust Inc. increased its position in Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after buying an additional 3,880 shares during the period. Headlands Technologies LLC lifted its stake in Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after buying an additional 4,853 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after acquiring an additional 478 shares during the period. Finally, Mount Yale Investment Advisors LLC bought a new position in shares of Genmab A/S during the third quarter worth about $192,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Trading Down 0.2 %

Shares of GMAB opened at $20.09 on Friday. Genmab A/S has a 12-month low of $19.85 and a 12-month high of $32.88. The firm has a market cap of $13.29 billion, a PE ratio of 19.51, a price-to-earnings-growth ratio of 0.67 and a beta of 0.96. The company’s 50 day simple moving average is $21.87 and its 200-day simple moving average is $24.87.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter last year, the business posted $0.47 EPS. As a group, equities research analysts forecast that Genmab A/S will post 1.28 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.